What the FDA labels say about taking them together
Cobicistat and nevirapine
Cobicistat's FDA label of February 10, 2026 names nevirapine in its contraindications section; the nevirapine label PlainMeds reads does not name cobicistat. The cobicistat label: “Contraindicated with TYBOST coadministered with atazanavir only: Coadministration of atazanavir with nevirapine is contraindicated due to potential for loss of atazanavir therapeutic effect and development of …”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the nevirapine FDA label on DailyMed (effective July 15, 2026, Mylan Pharmaceuticals Inc.).
What does the cobicistat label say about nevirapine?
Cobicistat label, contraindicationsSt. John's wort ( Hypericum perforatum ) Hormonal Contraceptives: drospirenone/ ethinyl estradiol Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Non-nucleoside Reverse Transcriptase Inhibitor: nevirapine Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as Revatio ® for the treatment of pulmonary arterial hypertension Protease Inhibitor: indinavir Sedative/hypnotics triazolam, orally administered midazolam Coadministration with certain drugs for which altered plasma concentrations are associated with serious and/or life-threatening events or loss of therapeutic effect.
Cobicistat label, drug interactionsConcomitant Drug Class/Drug Name: nevirapine; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↓ atazanavir ↑ nevirapine ↓ cobicistat darunavir: effect unknown; Clinical Comment: Contraindicated with TYBOST coadministered with atazanavir only: Coadministration of atazanavir with nevirapine is contraindicated due to potential for loss of atazanavir therapeutic effect and development of resistance, and potential for nevirapine-associated adverse reactions. TYBOST coadministered with darunavir: TYBOST coadministration with nevirapine and darunavir is not recommended because it may result in the loss of therapeutic effect and development of resistance to darunavir.
Cobicistat label, warnings and precautionsMore than one antiretroviral that requires pharmacokinetic enhancement (i.e., two protease inhibitors or a protease inhibitor in combination with elvitegravir) Darunavir in combination with efavirenz, nevirapine, or etravirine Atazanavir in combination with etravirine Atazanavir in combination with efavirenz in treatment-experienced patients Darunavir 600 mg twice daily Other HIV-1 protease inhibitors including fosamprenavir, saquinavir, or tipranavir TYBOST in combination with fixed-dose combination tablets that contain cobicistat is not recommended.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the nevirapine label say about cobicistat?
Nevirapine's label (effective July 15, 2026) does not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nevirapine), Mylan Pharmaceuticals Inc., effective July 15, 2026 (SPL set c6e93829-7024-48f6-8023-da6ff27dfc0a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Nevirapine | |
|---|---|---|
| Labeled for | HIV | HIV |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.147 per tablet 200 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once